Consulting Report

This study was intended to identify and analyse inefficiencies and bottlenecks that undermine health systems' sustainability and potential policy solutions to tackle them.


Founded in 2002, OHE Consulting
provides client-focused, specialised
expertise on policy and strategic issues
affecting the delivery of health care
and the future of the pharmaceutical
and life sciences industries

We are dedicated to providing objective,
independent advice to help
our clients achieve their objectives.

O’Neill, P., Puig-Peiro, R., Mestre-Ferrandiz, J. and Sussex, J.

Consulting Report
October 2012

Since 1996, in its yearly PPRS Report to Parliament, the Department of Health in England has published international price comparisons of branded medicines used in the primary care setting. OHE Consulting uses the same methodology in this report to update comparisons through 2011.

Mestre-Ferrandiz, J., Mordoh, A. and Sussex, J.

Consulting Report
June 2012

This report provides a clear explanation of the nature of innovation in medicines.  A fully revised and expanded version of the 2005 edition, it updates the literature review of the economics of innovation, traces important innovation that has occurred since 2005, adds new case studies and updates the discussion of competition in pharmaceutical R&D.

O'Neill, P., Devlin, N. and Puig-Peiro, R.

Consulting Report
January 2012

According to the 1999 UK Department of Health consultation document, the fundamental purpose of the National Institute for Health and Clinical Excellence (NICE) was to reduce inequalities in access to innovative care and ensure more rapid access to medicines identified as being of value to the NHS. Since NICE’s debut in April 1999, several analyses have examined the uptake of technologies that have been considered by NICE, but no evidence has yet been published on whether and how NICE’s health technology appraisal (HTA) processes may have affected the speed of access to new treatments.

Baillie, L., Hawe, E., O'Neill, P. and Greville, R.

Consulting Report
November 2011

In this, report commissioned by the ABPI in Wales, OHE Consulting examines the use of medicines in primary care in Wales since 2000 compared to the other countries of the UK.

Garau, M., Mordoh, A. and Sussex, J.

Consulting Report
April 2011

Continuing concern about the fiscal deficit makes it likely that government funding of health and medical research will remain under scrutiny. This OHE Consulting study, commissioned by Cancer Research UK, explores the interdependence between publicly funded and charity funded medical research.  In particular, it focuses on whether and how changes in the levels of government funding can affect private funding for charities, medical research and the UK economy as a whole.

Towse, A., Devlin, N., Hawe, E. and Garrison, L.

Consulting Report
January 2011

This report examines and makes suggestions for the appropriate use of health technology assessment (HTA) in emerging markets. In particulary, it considers how the stage of development of the health care system affects the relevance and appropriate use of various types of HTA. The approach developed then is used to analyse the options for Brazil, China and Taiwan.

Mestre-Ferrandiz, J., Garau, M., O'Neill, P. and Sussex, J.

Consulting Report
November 2010

This report examines the effect of the European Union’s 1999 Regulation on Orphan Medicinal Products (OMPs) on the European economy and society.  This study collected data on several indicators of activity, completed a confidential survey of companies developing OMP, concluded four case studies and undertook a literature review.  The result is a rich tableau of data and information that describe the effects of the OMP Regulation in some detail.  Findings include the following.

Sussex, J., Shah, K. and Butler, J.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and implications of central purchasing for economic efficiency.


Subscribe to RSS - Consulting Report